Digoxin

Pleurisy root as pleurisy root and other plants in the aesclepius genus contain cardiac glycosides, it is best to avoid use of pleurisy root with heart medications such as digoxin.
AUC of digoxin after i.v. dosing as a function of basal and rifampin-induced PGP-expression. And 6 were females. 9 supracardiac, 13 infracardiac, 3 cardiac and 2 mixed type comprised the group. Obstruction was seen in 24 patients. All the patients had severe pulmonary artery hypertension. Of interest is the fact that there were 3 neonates with pulmonary hypertension, without obstruction. Supracardiac types were obstructed either at the junction of the common venous chamber and vertical vein3 or at the junction of the vertical vein with the innominate vein or the superior venacava5, or at the inter-atrial communication1. In cardiac TAPVC, the obstruction was at the inter-atrial communication in 2 patients and at the junction of the common chamber and coronary sinus in 1 patient. All infracardiac TAPVC were obstructed as the descending vein passed through the diaphragm. Preoperative assessment included clinical evaluation, measurement of oxygen saturation, chest x-ray and echocardiography. Cardiac catheterization was not done in any patient. Pulmonary venous drainage was classified as obstructed when there was narrowing of the drainage of the common venous chamber as defined by two-dimensional echocardiography with a mean Doppler gradient of 5mmHg1. Patients with restrictive atrial septal communications and all patients with infradiaphragmatic TAPVC were also classified as obstructed. Pulmonary artery hypertension was defined, as right ventricular systolic pressure of more than 50 mmHg by Doppler measurement of tricuspid regurgitation jet. In the absence of good signal the septal position at the end of systole was used to indirectly assess the right ventricular systolic pressures 10 . Preoperative stabilization involved decongestive medications digoxin and diuretics ; and with judicious use of oxygen and when indicated, antibiotics and mechanical ventilation. Surgical technique Standard cardiopulmonary bypass with aorto-bicaval cannulation with profound hypothermia was instituted in all cases. Alpha stat strategy was used in all cases. A haematocrit of 3035 was maintained in all cases. Pericardium was harvested for subsequent closure of atrial septal defect ASD ; . Cold hyperkalemic sanguineous cardioplegic arrest was achieved and repair done under low flows. Circulatory arrest, although used for the initial cases, was not preferred in later cases as experience increased. Ductus arteriosus was divided. Patient was then cooled to the requisite temperature. During the cooling phase, the common chamber and vertical vein, if any, were dissected. Repair was accomplished after cardioplegic arrest, depending and dipyridamole. In 2004, and the resident accepted the dietary supplement drink. A physical examination was completed on April 12th, 2004 with recommendations that the resident's supportive regimen be continued. According to the record, on May 4th, 2004, the resident had a cast on his leg and weighed 131 pounds, and 134 pounds on May 22nd and on May 26th. The facility's registered dietician was informed of the resident's three pound weight gain. A May 26th, 2004 physician's order reflected that the resident should be weighed weekly and his meals monitored. His weight was recorded as 137 pounds on June 1st and 134 pounds on June 4th without the leg cast. Double food portions were added to his meals on June 9th, and he weighed 131 pounds on June 15th, and 135 pounds on June 22nd and on June 29th. A July 1st, 2004 discharge note from Century Village stated that the resident had maintained his weight, according to the registered dietician and the meal-monitoring program. The note further expressed that the medical physician was notified that the meal-monitoring program was no longer needed. At the site visit, the Director of Nursing DON ; reported that the facility has a registered dietician. Residents are weighed monthly and physicians are notified immediately of any significant weight loss or gain. She explained that residents are placed on a meal-monitoring program and weighed weekly if appropriate. The DON stated that the resident in the complaint did not lose any significant weight. The facility's policy for monitoring and reporting weight states that all residents will be weighed using the same scale and the same manner each month. A weight team is responsible for weighing residents, and they will be weighed monthly, as ordered, and upon admission and readmission. All monthly weights will be completed and forwarded to the DON or designee by the 10th of each month. The DON will return the list of reweighs to the weight team by the 15th of every month, and the reweighs will be returned to the DON by the 20th of each month. A list of the significant weight changes will be given to the dietary department and the dietician by the 20th of each month. Dietary recommendations will be given to the DON and forwarded to the Health Care Practitioner. The complaint further alleged that the resident had suffered a stress fracture and cellulitis on his foot from psychotropic medications side effects. The resident's care plan indicated that he was at risk for falling due to psychotropic medications. He was to be observed for functional decline and instructed on safety. He also required close supervision because of problems with violence and anger. Psychotropic medications were to be administered as ordered, and side effects such as lethargy and loss of appetite, were to be monitored. On April 5th, 2004, a progress note stated that the resident fell on the elevator, and the medical physician and the guardian were notified. An ice pack was applied to his swollen left leg. An x-ray of the resident's left hip, foot and knee on the next day. Special tip for filling out medical forms one shhh member reports that when filling out medical questionnaires, she lists ototoxic medications under known allergies and persantine, for example, digoxin hypokalemia.

Meds types irregular heart online-free : $2 60 prescription lanoxin non required diogitran diogitran fda rx medstore digoxin lanoxicaps lanoxin -heart arrhythmias and motilium.
Abbreviated process to expedite and facilitate the development and approval of generic drugs. The Hatch-Waxman Act permits a generic drug manufacturer to file an Abbreviated New Drug Application "ANDA" ; that incorporates by reference the safety and effectiveness data developed and previously submitted by the company that manufactured the original, pioneer drug. 40. The Hatch-Waxman Act provides an economic incentive to the, for example, digoxin oral. 12.4 Medicines used in heart failure digoxin tablet, 62.5 mg, 250 mg oral solution, 50 mg ml injection, 250 mg ml in 2-ml ampoule enalapril hydrochlorothiazide tablet, 2.5 mg scored tablet, 25 mg powder for infusion, 50 mg in ampoule and doxepin. 177. Frykman V, Ayers GM, Darpo B, et al. What characterizes episodes of atrial fibrillation requiring cardioversion? Experience from patients with an implantable atrial cardioverter. Heart J 2003; 145 4 ; : 6705. 178. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49 1 ; : 4759. 179. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Coll Cardiol 1999; 33 2 ; : 30410. 180. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Coll Cardiol 2003; 42 11 ; : 194451. 181. Benaim M. Asystole after verapamil. BMJ 1972; 2: 169. Simpson CS, Ghali WA, Sanfilippo AJ, et al. Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. Heart J 2001; 142 2 ; : E3. 183. Roth A, Kaluski E, Felner S, et al. Clonidine for patients with rapid atrial fibrillation. Ann Intern Med 1992; 116: 38890. Boriani G, Biffi M, Diemberger I, et al. Rate control in atrial fibrillation: Choice of treatment and assessment of efficacy. Drugs 2003; 63 14 ; : 1489509. 185. Agarwal AK, Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001; 3 4 ; : 43740. 186. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR XL randomized intervention trial in congestive heart failure MERIT-HF ; . JAMA 2000; 283 10 ; : 1295302. 187. Fung JW, Chan SK, Yeung LY, et al. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002; 4 ; : 48994. 188. Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol 2001; 28 5-6 ; : 44650. 189. Wattanasuwan N, Khan IA, Mehta NJ, et al. Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. Chest 2001; 119 2 ; : 5026. 190. Chiladakis JA, Stathopoulos C, Davlouros P, et al. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001; 79 23 ; : 28791. Each 38 mg vial will bind approximately 0.5 mg digoxin or digitoxin ; 1 Digooxin immune Fab interferes with digoxin immunoassay. Standard measurements of digoxin may not be reliable for up to 2 weeks after treatment, especially in patients with renal impairment3 IM or subcutaneous administration: not applicable and sinequan.

Risk management continued ; a ; Credit risk management continued ; Credit authorities are delegated to individual approvers for efficiency and productivity purposes. Except for taxi loans, small business loans and consumer loans, no business originating units can singly approve any loan. Loans singly approved by business originating units are nevertheless still subject to approval criteria pre-set by the Credit Function or Credit Committee. Otherwise, the Group generally requires "Dual" approval whereby loan proposals shall require joint approval by the Business Line and Credit Function. The Bank's Credit Committee, which approves all credit policies and large loans, shall not pass any credit related proposal if its Credit Function approvers disagree. Only the loan proposals approved by Credit Committee would be submitted to Chief Executive Officer for signature if and where it is needed. The Credit Analysis and Administration Department is the centralized department in the Bank mandated to carry out credit policies. It performs independent credit assessment, postapproval credit administration and other credit control functions to ensure that the credit process complies with credit policies and guidelines laid down by the management. Apart from the independent credit assessment and matrix approval process, regular post approval inspection by Risk Management Department and credit audits are conducted on specific loan portfolio or operating units in the credit process. To maintain its independence, the Credit Analysis and Administration Department of the Bank has a direct reporting line to a Deputy General Manager independent of business. The management spares no efforts in monitoring the quality and behavior of the loan portfolio. The Group's internal credit risk grading system consists of 15 grades built on Basel II compliant attributes is adopted for credit risk differentiation purpose. With internal data to be constantly enriched through years of experience, it is expected that the Group can make further use of the credit statistics to profile and track down credit risk migration, to measure loan default probabilities and to practise other credit risk management processes, of which the new credit rating model is and will substantially be an integral part. b ; Liquidity risk management Liquidity risk is the risk that the Group cannot meet its financial obligations as and when they fall due. Liquidity risk management is therefore to ensure adequate cash flows to meet all financial obligations under both normal and contingency circumstances in a cost-effective manner and within regulatory requirements. To manage liquidity risk, the Group has established asset and liquidity management policies that are reviewed by the relevant functional committees, with prominent issues approved by the Board of Directors. Liquidity is also managed and forecast on a daily basis to enable Treasury and Markets "T&M" ; and the relevant functional committee to act proactively according to changing market conditions and to implement contingency plans on a timely basis. Stress tests are regularly performed to assess contingent funding needs and the adequacy of funds to meet them. In case of shortage identified, corresponding remedial measures will be planned. To strengthen our liquidity risk control, a software system is in installation by which the Bank will be in a better position to predict its funding position. The Group continues to explore and diversify funding channels to capitalise on opportunities for the Group's business expansion. Concrete funding availability from the parent company, ICBC, is proven in strengthening our liquidity capability. As at 30 June 2007, the Group has a total of approximately HKD8.7 billion certificates of deposit issued to secure longer term funding. The liquidity position remained affluent throughout the first half of 2007 with an average liquidity ratio at 43.7% Average for the first half of 2006: 42.7% ; , that was well above the statutory requirement of 25. Additional monitoring of your dose or condition may be needed if you are taking amiodarone, blood thinners such as warfarin, bosentan, cyclosporine, dalfopristin or quinupristin, digoxin, diltiazem, fluconazole, imatinib, rifamycins such as rifampin, st and vibramycin. Side Effects: Interactions: PEARLS: Standard medical control and deviation guidelines apply unless otherwise stated. To prevent tissue necrosis, make sure to administer the drug through an IV that is patent and flowing well. Flush well between administration of calcium & sodium bicarb to avoid precipitate. May sometimes be requested by medical control to be coadministered with Cardizem to offset hypotension in hypotensive patients. Precipitates with sodium bicarbonate, epinephrine and potassium phosphate When given to a patient on Digoxin, can cause elevated Dig9xin levels and possibly digitalis toxicity. May antagonize the effects of Verapamil. Metallic taste Burning "Heat waves" Bradycardia may cause asystole ; Hypotension Cardiac arrhythmias Increased digitalis toxicity Extravasation with necrosis and sloughing Vasospasm in coronary and cerebral arteries. N V.
It is also important to tell your doctor if you are taking corticosteroids, anticoagulants drug that prevents blood clots, such as warfarin ; or rigoxin a drug used to treat heart problems ; . The safety of this medicine has not been established in adolescents and children and venlafaxine and digoxin. Lancet October 26, 2002; 360: Editorial, first author Robert J Myerburg, University of Miami School of Medicine, Miami, FL thelancet Comment: 1 "Rhythm Or Rate Control In Atrial Fibrillation--Pharmacological Intervention In Atrial Fibrillation PIAF ; : A Randomized Trial" Lancet November 25, 2000; 356: See abstract in Practical Pointers November 2000. The study contrasts the two approaches. Both have adverse effects as well as benefits: Rhythm control: Upside: If successful, no need for warfarin prophylaxis; exercise tolerance better. Downside: Requires drug or electrical conversion. Both may fail. Adverse effects of drugs to maintain sinus rhythm eg, amiodarone ; . High rate of withdrawal due to adverse effects. ; Reversion to AF common about 50% revert to AF within one year ; . Hospitalizations more frequent. Higher costs. Rate control: Upside: Simpler -- avoidance of cardioversion. Fewer adverse drug reactions. Fewer hospitalizations. Exercise tolerance lower. Lower costs. Downside: Continued drug therapy calcium blocker; digoxin; warfarin.

Yearly drug helps prevent fractures posted by roboblogger may 4, 2007 via intelihealth an osteoporosis drug taken once a year prevents fractures as well as older drugs, researchers say and epivir. 200 Not Med Nec The diagnosis clinical information does not support medical necessity. 271 300 Add info 400 Req Info The client is not eligible for Colorado Medical Assistance Program coverage on all or part of the dates covered by the PAR. Verify eligibility prior to rendering services. The requested additional information is insufficient. More information is required to complete your PAR. The requested information was not submitted. You may submit a new PAR with the required information.
Table 9. Summary of Transaminase Elevations. Of pharmacy student learning: development and implementation. 358E Burniske Gail M: Post-discharge follow-up phone call by a pharmacist and impact on patient care. 375 -CCaballero Joshua: Atypical antipsychotic treatment in Alzheimer's disease: effect on cognition. 285 Caballero Joshua: Effect of antidepressants on cognition in Alzheimer's disease. 97 Carnahan Ryan M: A longitudinal study of atypical antipsychotic prescribing patterns in the Iowa Medicaid population. 295E Carr Roxane R: Pamidronate therapy in children with osteogenesis imperfecta and idiopathic juvenile osteoporosis. 225 Carroll Douglas N: Evaluation of serum figoxin concentrations in patients treated for heart failure. 31 Carter Orly: Merck Cardiovascular Fellowship: Evaluation of peak exercise tolerance, cardiac hemodynamics, and quality of life assessment from ribose versus placebo in subjects with left ventricular systolic with or without diastolic dysfunction. 427 Cassino Cara: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in COPD patients. 313E Cauffield Jacintha S: Pharmacy based activity to reverse and manage disease PHARMD ; : the hypertension project. 373 Cavallari Larisa H: Racial differences in spironolactone response. 24 Chan Holly: Implementation of a therapeutic substitution program for erythropoietic agents. 200 Chen A I: A pharmacokinetic PK ; model for nelfinavir NFV ; and M8 when coadministered with amprenavir APV ; and efavirenz EFV ; . 277 Chen Jack J: Fluoxetine-induced orobuccolingual dyskinesia and persistent mandibular dystonia treated with botulinim toxin type-A. 182E Chen Jack J: Rasagiline, a novel, potent, secondgeneration, selective, irreversible inhibitor of monoamine oxidase-B MAO-B ; , improves freezing of gait FOG ; in advanced Parkinson's disease PD ; patients receiving levodopa carbidopa LD CD ; . 186 Chen Jack J: Rasagiline, a selective, secondgeneration, irreversible inhibitor of monoamine oxidase type-B, is effective in patients older and younger than 65 years of age with early-toadvanced Parkinson's disease PD ; . 183 Chisholm Marie A: Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy. 326 Choudhri Shurjeel: Lack of clinically significant hepatotoxicity following moxifloxacin therapy. 129 Chung Eunice P: The effectiveness of using a worksheet to screen pneumococcal vaccine candidates and increase the rate of vaccination. 380 Chung Karen C: Cost-effectiveness of FEIBA vs NovoSeven as initial therapy for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors. 114E Churchwell Mariann D: Comparison of diffusive and convective transmembrane clearance with AN69 and polysulfone hemodiafilters in CVVH and CVVHD. 173E.
The exquisite sensitivity of panning to small differences in hapten structure and its potential as a method for engineering fine specificity changes in Ab combining sites. Specificity analyses Tables I and IV ; showed that several of these clones had affinities for gitoxin and 16-formylgitoxin that were significantly increased relative to wt; in some cases, heteroclicity for gitoxin was observed i.e. the mutants bind gitoxin with higher affinity than cigoxin ; . In addition, binding to 16-acetylgitoxin improved 35-fold. These results were unexpected, as C16 lies on the opposite side of the cardenolide from this segment of H: CDR3 Figure 4 ; . Substitutions of Arg for Trp at position H: 100 may not appear to be a conservative change, but the charged end of the arginine side chain would be able to project into bulk solvent, eliminating any unsatisfied electrostatic interactions. The extensive hydrophobic body of the arginine side chain can in turn act as a partial replacement for the more extensive hydrophobic surface of the wt Trp side chain. Arginine is inherently a much more flexible side chain than any of the aromatic groups, which may allow it to move within the binding pocket much more readily than the wt Trp or His mutant side chains. The results suggest that the increased flexibility of Arg is an important factor in two observed effects, the accommodation of 16-substituted haptens and mutations at H: Ala100a. The 16-position of digoxin projects toward part of the structure at the opposite side of the binding site to H: Trp100 and in particular toward the side chains of H: CDR1 and residue H: 100b of CDR3. Introduction of a larger group than hydrogen at the 16-position of the cardenolide pushes on that surface and in turn pushes the antigen against the residue at position H: 100 on the opposite side of the binding site. There is a clear correlation between the binding of 16-substituted digoxin analogs and the presence of Arg at position H: 100, which we propose is a direct result of the ability of the side chain to move to accommodate the shift of the hapten within the binding site. As stated above, substitution of larger side chains at H: Ala100a will also produce structural rearrangements of the antibody, probably involving backbone rearrangements. The location of side chains is critically dependent on the direction of the CC bond, in turn dependent on backbone conformation. Arg at H: 100 is the only side chain that is compatible with both hapten binding and the presence of larger H: 100a mutations. It can still maintain an acceptable affinity for the antigen via hydrophobic interactions, while changing local conformation in response to altering backbone conformation in H: CDR3. We previously examined sequence constraints for digoxin binding in 26-10 by constructing a bacteriophage library randomized in H: CDR1 Short et al., 1995 ; . Phage were selected by digoxin and three C16-substituted analogs. Although diverse sequences were consistent with high-affinity binding, H: Asn35 was highly conserved and no mutants with significant improvement in relative binding for C16-substituted analogs were recruited, even though this portion of H: CDR1 contacts the D ring of digoxin at C16. The finding in the work reported here, that instead, mutations on the opposite side of the cardenolide involving H: CDR3 resulted in specificity shifts for C16-substituted analogs, is counterintuitive and was not anticipated Figure 4 ; . An alternative hypothesis is that the C16-substituted analogs are rotated 180 in the mutant binding sites, so that the flipped C16 substitutions would point toward Arg100 and potentially form new hydrogen bonds to H: Arg100. 295.
Jose E. Nanez, Ph.D. Associate Professor of Psychology Arizona State University, West Dept. of Social and Behavioral Sciences 4701 West Thunderbird Road P.O. Box 37100 Phoenix, AZ 85069-7100 Judith K. Ockene, Ph.D. Director University of Massachusetts Medical School 55 Lake Avenue North Worcester, MA 01655 Nancy Rigotti, M.D. Director Tobacco Research and Treatment Center Massachusetts General Hospital General Internal Medicine Unit 50 Staniford Street, 9th Floor Boston, MA 02114-2698 Dale Sandler, Ph.D. Chief, Environmental & Molecular Epidemiology Section National Institute of Environmental Health Sciences Epidemiology Branch - MD A3-05 111 T.W. Alexander Dr.; P.O. Box 12233 Research Triangle Park, NC 27709 Wayne F. Velicer, Ph.D. Professor & Co-Director Cancer Prevention Research Center University of Rhode Island 2 Chafee Road Kingston, RI 02881-0808 Richard Warnecke, Ph.D. Director Professor Health Research and Policy Centers MC 275 ; University of Illinois at Chicago 850 West Jackson Blvd., Suite 521 Chicago, IL 60607-3025 and dipyridamole.

Digoxin alcohol Patients in complete remission was significantly greater with balsalazide at weeks 4 38% vs 12% ; , 8 54% vs 22% ; and 12 62% vs 37% ; . Patient satisfaction and time to first symptom-free day were also superior with balsalazide. Adverse Effects Contraindications In trials, balsalazide was generally well tolerated with side effects expected of an aminosalicylate, namely headache 8.6% ; , abdominal pain 7.4% ; , diarrhoea 5.1% ; , nausea 4% ; and vomiting 3.4% ; 6. Although not observed in trials, rare reactions such as blood dyscrasias, nephrotoxicity, acute pancreatitis, hepatitis and allergic reactions including rashes have been observed with similar drugs and are possible side effects with balsalazide. Comparative trials showed a lower incidence of side effects than sulphasalazine. One trial against mesalazine showed no difference in the incidence or severity of adverse effects4 although in the other trial, significantly fewer patients taking balsalazide reported an adverse event 48% vs 71% ; 5. Balsalazide is contraindicated in patients with severe renal impairment or with a history of hypersensitivity to salicylates, mesalazine or any ingredient in the product6. It should not be used in pregnancy or lactation. It should be used with caution in patients with moderate renal impairment or established hepatic disease. Salicylates may worsen asthma, therefore asthmatic patients should be monitored carefully6. Interactions Patients on digoxin should have their digoxin levels monitored when starting balsalazide6. Xlpharmacyrx , drug information an interactions. Inflammatory drug, the nurse must monitor the patient for . A. agitation, which indicates nervous system involvement B. urinary retention, which indicates renal insufficiency C. decrease in WBC count, which increases the risk for infection D. gastrointestinal symptoms, which can be serious and sometimes fatal.

Prescription Drugs Digoxin Tablet 62.5 micrograms Digoxni Tablet 250 micrograms Difoxin oral solution 50 micrograms ml; injectioin, Diboxin 250micrograms ml in 2 ampoule Dopamine Injection 40 mg hydrochloride ; in 5 ml vial Hydrochlorothiazide Tablet 25 mg Hydrochlorothiazide Tablet, 50 mg DERMATOLOGICAL MEDICINES topical ; Antifungal medicines Miconazole Ointment or cream, 2% nitrate Sodium thiosulphate Solution 15% Anti-infective medicines Methylrosanilinium chlorode gentianviolet ; Aqueous solution, 0.5%; tincture 0.5% Neomycin sulphate + bacitracin Ointment 5 mg neomycin sulfate + 500 IU bacitracin zinc g Potassium permanganate Aqueous solution 1: 10 000 Silver sulfadiazine Cream, 1% in 500 g container Tr. Benzoin Anti-inflammatory and antipruritic medicines. Digoxin ointment Medical treatments like glaucoma, scarring, of the ear and pain , probably by decreasing, because digoxin class. Digoxin ointment Based on an evaluation of the currently available published information there is insufficient evidence to add duloxetine to the joint Primary Secondary Care Preferred Drugs List, or to the Nottinghamshire Healthcare Trust Preferred Prescribing List at the present time. Although belonging to the same SNRI antidepressant class as venlafaxine it would be premature to use duloxetine as an alternative to venlafaxine in light of the lack of comparative efficacy data and current safety concerns with venlafaxine. This recommendation will be reviewed by the Nottinghamshire Healthcare Trust in light of future published information on duloxetine. Duloxetine is also licensed under the brand name of Yentreve for moderate to severe stress urinary incontinence in women. The packaging, appearance, formulations and recommended daily dosage of Yentreve in stress urinary incontinence are different to that for Cymbalta in depression. A copy of the full evaluation undertaken by pharmacists Sharon Longbottom and John Lawton can be obtained from John Lawton, Clinical Pharmacy Services Manager, Nottinghamshire Healthcare Trust, Wells Road Centre. THE ROUGH GUIDE TO DIGOXIN The Department of Health produced the document `Building a safer NHS for patients' to support the commitment to reduce the frequency of serious medication errors by 40%. The prescribing of potentially toxic medication, with a narrow therapeutic window, is always an area where greater care should be taken. Digoxin is a medication that fulfils these criteria, and is a medication that has been involved in recent errors.

Sera from 10 patients [7 from the gastroenterology department and 3 from the anesthesiology intensive care unit ICU ; ] receiving 100 600 mg of K-canrenoate per day, mostly for the treatment of ascites as a consequence of cirrhosis of the liver, were tested for interference in the AxSYM assay. Digoxin-like immunoreactive factor DLIF ; is often present in such patients and has been reported to suppress MEIA results 11, 12 ; and cause a positive interference in the Emit assay 13 ; . Several other studies, however, have not been able to reproduce the latter findings 14 16 ; . Before digoxin was added, there was no Emit result in excess of 0.5 g L, indicating that the strong inhibition of the AxSYM assay observed after the addition of digoxin was primarily attributable to the presence of canrenone and not DLIF recovery, 35 81%; total mean, 60% ; . The observed inhibition of the AxSYM assay in these 10 patients increased with higher doses 100, 200, 400, and 600 mg ; of K-canrenoate per day. Co-adminstration of multiple doses of atorvastatin and digoxin increased steady-state plasma digoxin concentrations by approximately 20.